

Special Issue

Cancer Immunotherapy in Clinical and Translational Research

Message from the Guest Editor

Immune checkpoint inhibitors and adoptive cell therapies have significantly improved the survival of patients affected by some of the deadliest tumors. Due to their established anticancer activity, these treatments currently represent one of the main therapeutic options in several oncological settings. Nevertheless, a significant proportion of cancer patients do not respond to immunotherapy. The incorporation of novel biomarkers and the implementation of adapted study designs specific for immunotherapy-based treatments could increase the success rate of this class of agents. We are pleased to invite you to contribute to this Special Issue focusing on clinical and translational research in cancer immunotherapy. Original research articles and reviews are welcome. Research areas may include but are not limited to preclinical, translational and clinical studies involving multi-omic techniques, liquid biopsies and microbiome studies. Articles exploring innovative strategies for adapting clinical trial design for immunotherapy development will also be accepted. We look forward to receiving your contributions.

Guest Editor

Dr. Sofia Genta

Kingston Health Sciences Centre, Kingston, ON K7L 2V7, Canada

Deadline for manuscript submissions

31 December 2024



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/197151

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)